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ABstRACt
Objective: There is no other screening program close to the success rate of PAP test. Cervical cytology constitutes a large workload so that quality 
control in cervical cytology is important for the quality assurance of pathology laboratories. 
Material and Method: In this study, we collected the cervical cytology results from all over Turkey and discussed the parameters influencing the 
quality of the PAP test. The study was conducted with Turkish gynaecopathology working group and 38 centers (totally 45 hospitals) agreed to 
contribute from 24 different cities. The study was designed to cover the cervical cytology results during 2013. The results were evaluated from 
the data based on an online questionnaire.
Results: The total number of epithelial Cell Abnormality was 18,020 and the global epithelial Cell Abnormality rate was 5.08% in the total 354,725 
smears and ranging between 0.3% to 16.64% among centers. The Atypical squamous cells /squamous intraepithelial lesion ratios changed within 
the range of 0.21-13.94 with an average of 2.61. When the centers were asked whether they performed quality assurance studies, only 14 out of 
28 centers, which shared the information, had such a control study and some quality parameters were better in these centers.
Conclusion: There is an increase in the global epithelial Cell Abnormality rate and there are great differences among centers. Quality control 
studies including the Atypical squamous cells/squamous intraepithelial lesion ratio are important. Corrective and preventive action according 
to quality control parameters is a must. A cervical cytology subspecialist in every center can be utopic but a dedicated pathologist in the center 
is certainly needed.
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IntRODUCtIOn
Cervical cancer has shown a decreasing incidence since the 
use of the Papanicolaou (PAP) test starting at the 1950’s. 
According to the GlObOCAn 2012 database, cervical 
cancer is the 7th most common cancer in the world and 
4th among women (1). According to the 2012 data of the 
Cancer Department of the Health Ministry of Turkey, it is 
the 10th most common cancer among women with a 2.4% 
incidence rate (2). 
since the use of the PAP test, there has been no other screening 
program with a similar success. There is a population-based 
screening program carried out by the Ministry of Health 
in Turkey, but hospital-based (opportunistic) screening 
still constitutes a great volume in cervical cancer screening. 
There are several articles representing the hospital-based 
results of cervical cytology from different centers (3-13) and 
one multi-center study representing data from 33 centers 
comprising 140,334 patients in Turkey (14). 
Cytology slides are usually evaluated by pathologists and 
only few centers have cytotechnologists in Turkey. Cervical 
cytology constitutes a large volume in the workload within 
the pathology routine so that quality control in cervical 
cytology is important for the quality assurance (QA) of 
the pathology laboratories. There are several proposed 
quality control parameters for cervical cytology such as 
cytology histology correlation (CHC), retrospective review 
of negative smears that have a following positive biopsy, 
monitoring diagnostic rates, multi-head review of difficult 
cases, and high risk Human Papilloma Virus (hrHPV) 
positivity of atypical squamous cells of undetermined 
significance (AsCus) cases (15). Two reliable and widely 
used criteria are the Atypical squamous cells (AsC)/
squamous intraepithelial lesion (sIl) ratio and CHC. 
AsC is expressed as the total of AsCus and AsC – cannot 
exclude High grade squamous Intraepithelial lesion (HsIl) 
(AsC-H) (16-18). The recommended AsCus/sIl ratio 
is 2 to 3 in different publications (16,19,20) and between 
0.87 and 4.49 in others (16,20,21). The reported hospital 
based ratios from Turkey vary between 3.28 and 12.6 (3-13) 
and 2.83 in the multi-center study of the Turkish Cervical 
Cancer and Cervical Cytology research Group (14). 
The CHC is another important parameter to be followed 
in terms of QA. In 90.8% of the patients with a positive 
cervical cytology, sIl was determined on biopsy and the 
biopsy was found to be normal in 62.8% of the cases where 
no epithelial cell abnormality (eCA) was seen on cytology 
(22).  The CHC increases in direct proportion with the 
increase of atypia degree on cytology and can be as high 
as 100% for HsIl  and decreases to 54% for AsCus and to 
20% for atypical glandular cells (AGC) (4,6,7,9,23,24). 
The workload is also an important determinant affecting 
the quality parameters in pathology. The workload limit 
can vary; it is reported to be assessed by daily or hourly 
slide number, time spent nonstop on screening or daily 
total time of screening (25). The daily workload of cervical 
cytology is important, but the more correlated parameter is 
reported to be the eCA-adjusted workload of 7 slides/day, 
which means 70 slides/day with a 10% eCA (26). 
Cervical cancer screening is very important and several 
methods can be used. In Turkey, cervical cancer screening 
is mostly by opportunistic hospital-based screening. There 
are studies for public based screening. The first studies 
with this aim were based on the cervical PAP smear test. 
However, the current method in Turkey is HPV screening, 
and the cervical smear is evaluated if the patient is HPV 
positive (27). 
In this study, we aimed to collect the cervical cytology results 
from all over Turkey to represent the whole country data as 
close as possible and discuss the parameters influencing the 
quality of the PAP smear reporting.
MAteRIAl and MetHODs
The study proposal was shared with Turkish 
gynaecopathology working group and all the laboratories 
were asked to contribute to the study. Thirty-eight centers, 
one of which having 8 different hospitals (in total 45 
centers), from 24 different cities agreed to contribute to the 
study. The study was designed to cover the cervical cytology 
results within the period of 1 January-31 December 2013. 
An online questionnaire was conducted. laboratories 
were asked to state their annual biopsy/cytology/cervical 
cytology counts, method of cervical cytology, pathologist 
number responsible for PAP smear and number of total 
pathologists, annual diagnoses of eCA with subgroups of 
AsCus, AsC-H, low grade squamous intraepithelial lesion 
(lsIl), HsIl, AGC and carcinoma (CA). Additionally, the 
biopsy or follow-up PAP smear results of the patients for 
whom the eCA diagnosis was available were collected.
The eCA and AsC/sIl ratio were calculated from 
participant-reported data. The eCA rate was defined by the 
ratio of eCA to the total cervical cytology number. AsC/sIl 
defined by the ratio of the sum of AsCus and AsC-H to the 
sum of lsIl, HsIl, and CA cases. 
ResUlts
The study group was composed of 38 pathology laboratories 
and 45 different hospitals from 24 cities. The participant 
distribution is shown in Figure 1. Among the participant 
centers, 12 (26%) were state hospitals while 8 (18%) were 
private hospitals and 25 (56%) were university hospitals. 
The annual total number of smears was 354,725 and cervical 
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The annual total number of eCA was 18,020 in the study 
group and the global eCA ratio of the study group was 
5.08% in the total 354,725 smears. Among the centers, the 
lowest reported eCA rate was 0.3% and the highest eCA 
was 16.64%. The eCA rates of the laboratories are shown 
in Table I. The distribution of eCA rates varied among 
the geographic regions (Figure 2). The relation between 
the eCA rates and the total smear number is shown in 
the graph (Figure 3). When analyzed based on the type 
of the centers, eCA rate varied between 0.52 and 7.76% 
(mean: 2.81%, median: 2.18%) in state hospitals while it 
was 3.71-16.64% (mean: 12.32%, median: 14% ) in private 
hospitals and 0.39-14.57% (mean: 3.16%, median: 2.38%) 
in university hospitals.
cytology numbers of the laboratories ranged between 674-
49,483 (Table I) while total annual biopsy numbers were in 
the range of 5827 to 155,497. The cervical smear constituted 
28% of the total biopsy volume in average. The type of 
method used in cervical cytology was conventional smears 
in 18 and liquid based cytology (lbs) in 20 laboratories 
while 9 centers were using automated screening program. 
The number of pathologists working in the centers 
ranged between 1 and 30 and the number of pathologist 
responsible for cervical cytology were in the range of 1-13. 
The annual number of smears per pathologist varied from 
294 to 21,297. Working cytotechnologists were present in 
2 centers. Cervical cytology constituted 28% of the volume 
on average with a range of 8.87%-92.46%.
Figure 1: The participant 
distribution of the study.
Figure 2: The epithelial 
cell abnormality rates 
according to the 
geographic distribution.
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table I: The laboratory characteristics of the participants
Center 
number
number of 
pathologists
number of 
pathologist 
responsible for 
smear
Biopsy 
number
Cytology 
number
smear 
number
smear 
number/per 
pathologist
eCA 
ratio AsC/sIl
Q/A 
studies
1 5 1 15791 4935 2462 2462 2.03% 3.80 no
2 11 5 26217 9078 5427 1085 0.87% 4.00 no
3 5 5 16299 7034 6672 1334 3.03% 2.88 yes
4 8 7 54764 26293 19782 2826 4.49% 8.60 yes
5 2 2 5827 3324 2512 1256 0.52% 3.00 no
6 14 12 66817 32863 26113 2176 0.52% 0.79 no
7 4 4 26000 2000 6000 1500 1.20% 5.55 nA
8 2 2 11690 6104 5658 2829 1.98% 2.42 no
9 5 5 14469 5328 3315 663 8.51% 4.11 no
10 13 13 46060 18060 15986 1230 7.76% 4.27 nA
11 11 11 37501 16848 12598 1145 1.59% 2.75 nA
12 7 3 9966 2180 884 295 1.47% 5.50 yes
13 5 5 16055 1508 14845 2969 0.71% 10.88 no
14 9 4 29000 3859 8200 2050 0.78% 0.21 nA
15 15 2 31047 8112 6090 3045 0.39% 1.00 yes
16 8 8 37749 19326 5693 712 1.77% 3.41 yes
17 4 4 27655 14556 13843 3461 2.38% 0.87 yes
18 10 9 35348 12961 9502 1056 4.36% 6.21 yes
19 9 9 26740 11248 8468 941 1.55% 1.76 yes
20 3 3 10430 3834 2392 797 1.00% 2.43 nA
21 7 2 23489 5967 3200 1600 8.84% 13.94 no
22 6 5 25000 8500 6800 1360 3.01% 3.93 no
23 8 8 20869 2391 13023 1628 2.97% 0.81 no
24 7 1 19342 4918 2484 2484 1.25% 2.43 nA
25 19 6 36996 3492 6927 1155 1.26% 1.00 yes
26 6 6 25801 9398 6520 1087 3.17% 2.59 nA
27 13 11 31929 11635 8200 745 14.57% 1.74 nA
28 9 9 38328 3531 12770 1419 2.98% 2.97 no
29 5 5 33978 16865 8490 1698 2.92% 6.77 no
30 7 5 16562 6737 3457 691 3.67% 1.95 nA
31 13 1 37000 15000 9000 9000 2.40% 1.13 yes
32 15 3 45000 12500 6484 2161 2.88% 1.48 yes
33 5 4 16768 9690 6476 1619 5.54% 3.37 yes
34 30 3 155492 84715 63891 21297 14.10% 2.54 yes
35 4 4 11617 2417 1259 315 2.38% 2.75 no
36 6 2 16000 5500 3418 1709 2.11% 3.24 no
37 7 7 22000 13000 11954 1708 3.98% 2.30 yes
38 6 1 31799 12943 3930 3930 1.81% 3.12 nA
eCA: epithelial cell abnormality, AsC: Atypical squamous cell, sIl: squamous intraepithelial lesion, Q/A: Quality assurance, nA: not answered
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Figure 4: The AsC/sIl ratios distribution of the centers. 
AsC: Atypical squamous cell, sIl: squamous intraepithelial lesion).
Figure 5: The AsC/sIl ratio in relation to eCA rates of the centers.
AsC: Atypical squamous cell, sIl: squamous intraepithelial lesion, 
eCA: epithelial cell abnormality.
Figure 6: The AsC/sIl ratio in relation to annual smear number.
AsC: Atypical squamous cell, sIl: squamous intraepithelial lesion.
Among 18020 eCA, the most common lesion was AsCus 
(11557/18020, 64.2%) followed by lsIl (4106/18020, 
22.8%), AsCH (1029/18020, 5.8%), HsIl (700/18020, 
4%), AGC (548/18020, 3%) and CA (18/18020, 0.2%), in 
descending order.
The AsC/sIl ratios ranged between 0.21 and 13.94 with an 
average of 2.61 (±2.95) and median of 2.87. eight centers 
had an AsC/sIl ratio lower than 1.5 and 13 centers had 
a value between 1.5 and 3, while 7 centers had an AsC/
sIl ratio of 3-4 and 10 of them had a value higher than or 
equal to 4 (Figure 4). When analyzed according to the type 
of the centers, the AsC/sIl ratio varied between 0.79 and 
10.87 (mean: 4.23, median: 3.05) in state hospitals while it 
was in the range of 2.07-5.25 (mean: 2.08, median: 3.74) in 
private hospitals and 0.21-13.94 (mean: 3.17, median: 2.75) 
in university hospitals.
The graphical distribution of eCA percentages in relation 
to AsC/sIl ratios is shown in Figure 5.
The AsC/sIl ratios in relation to annual cervical cytology 
per pathologist in the centers are shown in Figure 6. 
When the centers were asked for whether they perform QA 
studies, 28 centers shared the information and 14 of them 
had such a control study.  eight centers were following the 
CHC results, another 5 were following both CHC and AsC/
sIl ratio and in 1 center the annual malignancy rate, AsC/
sIl ratio, and CHC rates were followed and 10% of negative 
reported cases were re-evaluated. In the QA-performing 
group, the AsC/sIl ratio range was 0.87-8.6 with an average 
of 3. In the QA-non performing group AsC/sIl ratio range 
was 0.79-13.94 with an average of 4.5. 
Figure 3: eCA rate distribution according to the total smear 
number of the center. 
eCA: epithelial cell abnormality.
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of cases with negative biopsy was 138. The biopsy results of 
1461 patients whose smear diagnosis had been lsIl were 
documented and sIl was verified in 1005 (726 lsIl, 276 
HsIl and 3 CA) (68.8%). The sIl verification rate by biopsy 
in patients diagnosed with HsIl was 87% (55 lsIl, 259 
HsIl and 48 CA). The positive predictive value (PPV) of 
AGC was 47.8% (14 lsIl, 9 HsIl and 35 CA and glandular 
pathology in 39 cases) and 97.4% (12 lsIl, 1 HsIl and 24 
CA) for carcinoma diagnosis. The biopsy follow-up results 
are shown in Table II.
The PPV of the each center according to the smear 
diagnosis showed variations. The lowest PPVs for AsCus, 
AsC-H, lsIl, HsIl, CA, and AGC were 9.5; 25; 25; 
66.6; 7.4, and 87.5, respectively. When these results were 
evaluated according to the AsC/sIl ratio, the PPVs for 
AsCus, AsC-H, lsIl, HsIl, CA, and AGC were 21-75.51-
85, 84-100, 84-100, 87.5 -100, and 28-100 respectively for 
the centers having an AsC/sIl ratio lower than 1.5. For the 
centers having an AsC/sIl ratio higher than 4, the PPVs for 
AsCus, AsC-H, lsIl, HsIl, CA and AGC were 9.5-44; 25-
51; 29-90; 66.6-100; 7.4-25 and 100, respectively (Table III).
When we analyzed the centers according to AsC/sIl higher 
than 3  and QA study performance, 35.7% (5 of 14) of the 
centers in the QA-performing group had an AsC/sIl value 
higher than 3 but this was as high as 57.1% (8 of 13) in the 
QA-non performing group. 
There were lower AsC/sIl ratios in private hospitals and 
no difference between university/non-university hospitals. 
Private hospitals had a common feature of having quality 
control studies in 5 out of 6 centers. Despite such QA 
studies, AsC/sIl was higher than 3 (3.37-3.41-5.5-6.21-8.6) 
in 5 out of these 14 centers. Among the 8 centers with AsC/
sIl ratios higher than 4, we found that 4 had no QA studies, 
3 were performing QA studies and no data was obtained 
from 1 of them.
Follow-up data of the patients was reported from 41 centers. 
In the study group, 4173 patients in total had at least one 
biopsy. Out of the 1951 biopsy-verified AsCus cases, 722 
were sIl and CA (559 lsIl, 152 HsIl, 11 CA) and the 
biopsy was negative in 1229 patients. Follow-up biopsy 
was performed in 344 patients reported as AsC-H and the 
results were 93 lsIl, 98 HsIl, and 15 CA while the number 
table II: The biopsy results of the patients with follow-up
smear 
Diagnosis
Biopsy Diagnosis
neG lsIl HsIl CA Glandular pathology (dysplasia, hyperplasia, polyp, etc.) total
Mean 
PPV
AsCus 1229 (62.9%) 559 (28.7%) 152 (7.8%) 11 (0.6%) - 1951 37.1
AsC-H 138 (40%) 93 (27%) 98 (28.5%) 15 (4.5%) - 344 60
lsIl 456 (31.2% 726 (49.7%) 276 (18.9%) 3 (0.2%) - 1461 68.8
HsIl 55 (13%) 55 (13%) 259 (62.5%) 48 (11.5%) - 417 87
AGC 106 (52.2%) 14 (6.7%) 9 (4.5%) 35 (17.3%) 39 (19.3%) 203 47.8
CA 1 (2.6%) 12 (31.6%) 1 (2.6%) 24 (63.2%) - 38 97.4
AsCUs: Atypical squamous cell of undetermined significance,  AsC-H: Atypical squamous cell-HsIl can not excluded, lsIl: low grade squamous 
intraepithelial lesion, HsIl: High grade squamous intraepithelial lesion, AGC: Atypical glandular cell, CA: Carcinoma, neG: negative, PPV: Positive 
predictive value
table III: The PPV of centers according to the diagnosis
literature (%) Centers that AsC/sIl is <1.5 Centers that AsC/sIl is >4 Centers that AsC/sIl is <4
AsCus 20-78 21-75 9.5-44 24-75
AsC H 42-83 51-85 25-51 33-100
lsIl 48-91 84-100 29-90 40-100
HsIl 75-100 84-100 66-100 76-100
AGC 10-50 28-100 7.4/25 29-100
CA 100 87.5-100 100 87.5-100
PPV: Positive predictive value, AsC: Atypical squamous cell, sIl: squamous intraepithelial lesion, AsCUs: Atypical squamous cell of undetermined 
significance,  AsC-H: Atypical squamous cell-HsIl can not excluded, lsIl: low grade squamous intraepithelial lesion, HsIl: High grade squamous 
intraepithelial lesion, AGC: Atypical glandular cell, CA: Carcinoma, neG: negative
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unfortunately, we do not have data from the eastern part 
of the country, and there is a gap in that area. There are 
studies representing data from this region (32) and the eCA 
rate was found to be 1.81% by those studies.  Although we 
cannot discuss the regional data, there is a lower eCA rate 
in this region of Turkey in comparison to the averages of 
the whole study group.
The differences in eCA rates among different cities show an 
increase in some cities on the coast. This can be attributed 
to socio-cultural differences. However, this cannot be the 
only explanation as there are low rates from the some cities 
such as Mersin, Adana, Istanbul and low rates reported 
from Izmir –another city on the coast. One striking result 
of the eCA rates is that a laboratory having 8 different 
hospitals reported the highest rates (shown in purple in 
Figure 2) among other hospitals in the same cities. In terms 
of QA, this laboratory has a highly acceptable AsC/sIl ratio 
smaller than 3, so the eCA rates can be considered reliable. 
This center is a private laboratory and most of the hospitals 
are A+ hospitals where the patient group consisted mostly 
upper socio-economic group of high-risk patients. This 
may reflect the difference in socio-economical difference 
among other centers. The data from this center is similar to 
the data of high income countries (28-30). 
The ranges of eCA rates showed no great differences when 
evaluated according to hospital type as public-private or 
university-nonuniversity hospitals. 
The AsC/sIl is reported to be less variable when compared 
to eCA and creates mathematical data recommended for 
use in QA (16,19,21). This ratio is recommended to be 1.73 - 
2.05 for cytopathologists and 0.87- 4.5 for cytotechnologists 
in several articles (16,21) and under 2-3 in others (16,19,20). 
The AsC/sIl ratio in hospital-based studies from Turkey 
varies between 2.25 and 12.6 (3-13). This value was 2.83 
in the multi-center study from Turkey (14). The AsC/sIl 
ratios from this study showed a great range among centers. 
The values changed from 0.21 to 13.94 with a mean of 2.83. 
When grouped, 8 centers had a ratio lower than 1.5 (21%) 
and 13 centers reported a ratio of 1.5-3 (34%). The number 
of centers having a ratio higher than 3 was 17 (45%) and 
9 of them had a ratio higher than 4. These values are not 
totally correlated to eCA percentages, as shown in the 
graph in Figure 5. It is seen that there are very low AsC/
sIl values in some high eCA reporting centers as well as 
high AsC/sIl values in some low eCA reporting centers, 
although the majority are grouped in the left part of the 
graph with acceptable values in terms of QA. It is stated that 
the AsC/sIl ratio may be lower in high-risk populations 
DIsCUssIOn
The time-honored PAP test is currently the most effective 
cancer screening method. The cervical smear data from 
Turkey is documented in hospital-based reports (3-13) and 
only one study (14) represents a multi-center data reporting 
results from 22 cities, 34 hospitals and a total of 140,334 
smears. There is an ongoing public-based national cervical 
carcinoma-screening program searching hrHPV presence 
since 2014, and the Turkish Ministry of Health runs it, 
but their data is not published yet. Hence our study is the 
largest existing study showing the results based on 354,725 
patients. 
Objective data is required in order to detect the efficiency 
of cervical smears. Various data such as the eCA rate and 
AsC/sIl ratio can be used for QA. When the eCA rate was 
evaluated, it varied between 1.5% and 7.3% in countries 
with high-income (28-30). reported rates from Turkey 
range from 1.2% to 12.6% (3-13) and were 1.8% in the 
multi-center study (14). The average eCA rate of 5.08% in 
our study is higher than the unreported current data of the 
Ministry of Health national screening program (31). This 
difference can be considered to be partly related to the 
patient population as our study used hospital-based rather 
than public-based data. To a smaller extent, possible patient 
duplications can be a reason, but our data was collected 
as patient-based, not test-based, and this cannot be the 
explanation for this high rate. Our study method is similar 
to the multi-center hospital-based study reported in 2009 
in Turkey (14) and our current results are also higher than 
this study. The difference may be attributed to the difference 
in hospital types, as the previous study did not include 
private hospitals, and the number of the patients involved 
in the studies. Our study includes 2.5 times more patients 
than the other study so we believe that our results are more 
reliable. As our study also includes private hospitals, we can 
also argue that our data represents a more homogeneous 
distribution among the Turkish population and hence 
it is more generalizable since the previous study did not 
represent the private hospitals that play a major role in the 
health care system. It is found that there is an increase in 
eCA rate in the 6-year period from 2007 (the data of the 
previous study shows the 2007 data) to 2013 (the year of 
data collection of the present study). The eCA rates of the 
private hospitals are seen to be higher than state hospitals, 
and this may be attributed to the upper socio-economic 
group of high-risk patients. This may reflect the difference 
in socio-economical difference among other centers, 
similar to the data of countries with high income (28-30). 
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Centers with an AsC/sIl ratio higher than 4 have another 
common property that cervical cytology was evaluated by 
all of the pathologists working in the laboratory and there 
was no dedicated pathologist in most of these centers. In 
89% of the centers that have a ratio higher than 4, cervical 
cytology is evaluated by all of the pathologists while only 
46% of the centers reporting low AsC/sIl values have 
such a working principle. based on this result, one can 
discuss whether cervical cytology should be reported by 
all pathologists or whether it should be a subspecialty or 
at least reported by some dedicated pathologist at the 
centers. In the pathology routine, cervical cytology is easily 
shared and with the current health performance system, 
every pathologist wants to evaluate it in order to “increase 
performance”. This is also discussed in other countries and 
it is stated that when health care professionals are paid for 
each service they provide, the health care neither becomes 
more efficient and well coordinated nor has high quality 
(33). 
Cervical cytology constitutes a large work volume of 
pathology routine and it made up an average of 28% 
of the patients in our study group. In this context, the 
adequacy of cytology training during pathology training 
should be discussed. At a survey of pathologists training 
in cytopathology in european countries (responded from 
26 countries), pathologists without specific training in 
cytopathology signed out cytology reports in 54.7%, more 
often in centers where training was 3-6 months or less in 
duration. However, 92.2% of respondents thought that 
cytology should not be reported by pathologists without 
experience in cytopathology (cervical cytology workloads 
of survey respondents varied from 500 to 200,000 requests 
per year; those defined as “large” processed a range of 
13,000-200,000 with an average of 38,000 per year) (34). 
Another important point to note is that cervical smears are 
accepted as the most efficient screening test and but are now 
becoming a somewhat “diagnostic” test due to the changing 
screening methods with the use of HPV typing as the first 
step. The curriculum of pathology residents should also be 
reviewed according to this changing profile.
In terms of QA of cervical cytology, the best parameter 
that can be used is eCA confirmed by cervical biopsy. 
The specificity and sensitivity rates of cervical cytology 
are reported to be highly variable (29,30,35). specificity is 
reported as 14 to 97% with a mean of 69% and sensitivity as 
11 to 99% with a mean of 58% in the literature (23,30,35,36). 
The CHC increases in direct proportion with the increase 
of degree of atypia on cytology to as high as 100% for 
HsIl, and decreases to 54% for AsCus and 20% for AGC 
and higher in low-risk populations (28). However, this 
statement cannot explain the difference in our study group, 
as there are centers with high AsC/sIl ratios although they 
have low eCA rates, as well as some low AsC/sIl ratios 
with high eCA rates. 
The workload is an important determinant, affecting the 
quality parameters in pathology. The workload limit can be 
variable, it can be assessed by daily or hourly slide number 
or time spent nonstop on screening or daily total time of 
screening (25). As well as the daily workload, a more highly 
correlated parameter is reported to be the “eCA-adjusted 
workload” as 7 slides/day, which means 70 slides/day with 
a 10% eCA (26). However, similar to eCA rates, the great 
range of AsC/sIl among centers in this study cannot be 
ascribed solely to workload as there are high values with 
low workload and very accurate values with very high 
workload. Figure 6 shows that there are very low AsC/sIl 
values in 2 high workload centers as well as AsC/sIl values 
higher than 4 in 7 centers that of which have a low workload 
of cervical cytology per pathologist although most of the 
centers are grouped in left part of the graph. The laboratories 
having the two highest values are different than the others, 
as they have cytotechnologists working with pathologists. 
Therefore, they can be evaluated separately. Other than 
these two highest volume centers, the annual PAP smear 
load is under 3000 cases in the 16 laboratories with AsC/
sIl higher than 3 when AsC/sIl ratio is evaluated in terms 
of the workload (defined by PAP smear per pathologist). 
so the AsC/sIl ratio cannot be said to depended on the 
workload, based on our study.
The QA is important in pathology laboratories as in all 
other fields. The Hawthorne effect describes the better 
performance of observed subjects than unobserved subjects 
and it is stated that pathologists in small laboratories 
working as solo screeners have the highest failure rate (15). 
Quality control studies were performed in 14 centers. There 
was no difference in parameters among hospital type, other 
than the low AsC/sIl ratios in private hospitals.  It is seen 
that this group has a common feature to have quality control 
studies in 5 out of 6 centers. It is obvious that this cannot be 
the only explanation but the effect of quality control studies 
cannot be denied. However, it is observed that AsC/sIl was 
higher than 3 (3.37-5.5-6.21-8.6) in 4 out of the 11 centers 
with quality control studies. In this context, it is noted that 
not only does the presence of quality control studies ensure 
quality but also the presence of corrective and preventive 
action is a must. Most of the centers declared they have 
QA studies documenting the CHC data required by the 
Ministry of Health. 
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(4,6,7,9,23,24). When PPVs are compared with the literature 
values, the mean rates of the study group are in accordance 
with the literature. low PPV values are noteworthy in the 
centers that had AsC/sIl > 4. Quality control studies and 
follow-up of the AsC/sIl ratio are important. However, 
the number of patients with biopsy follow-up varied. some 
centers that had very low follow-up numbers may therefore 
have appeared to have very high or very low PPVs.
In conclusion, this study shows that there is an increase 
in eCA rates in Turkey. There are great differences among 
centers. The most important result of this study is that 
QA studies including AsC/sIl are vital. However, QA 
activity does not mean to record the data to be sent to the 
Ministry of Health and taking corrective and preventive 
action according to quality control parameters is a must. 
A cervical cytology subspecialist in each center can be a 
dream at this stage but assigning dedicated pathologists for 
cervical cytology should be discussed and attempted. The 
pathology community should overview cervical cytology 
training during pathology residency and should be ready 
to the changing role of the pathologist in the future with 
cervical screening by hrHPV testing.
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